"Bet BSX wishes that they had skipped ACC2013," wrote 1 wag today at the Heart Rhythm Society’s annual meeting, after Boston Scientific presented clinical trial results showing that its Watchman device is safer and more effective than the anticoagulant drug Warfarin.
The news sent BSX shares to $8.25 apiece today, up 10.9% over yesterday’s $7.44-per-share close, representing a new 52-week high for the stock. Shares were trading at $8.23 as of about 3:25 p.m., up 5.1% for the day.